Orchid
Biocomputer is a privately held biotechnology company Orchid is fulfilling unmet medical needs through its proprietary pharmacogenetics and microfluidics platform technologies designed to accelerate the discovery and development of novel therapeutic and bioanalytic products.
The recent work of Russian physicists has further advanced the hypothesis that down to DNA and chromosomes, the human body represents a nonlocal holographic
biocomputer carrying out its functions via energy-wave phenomenon with speed far exceeding one of chemical reactions, equal to and even exceeding the speed of light.
Princeton, NJ 1/6/00-Orchid
Biocomputer has acquired GeneScreen, a genetic diversity analysis service.
Orchid
Biocomputer and SNP Consortium have entered into an agreement for Orchid to perform validation and quality control testing on genetic markers identified by SNP...Galileo announced that Andlinger Capital XIII purchased one million shares of company common stock as part of an equity financing agreement announced earlier this year.
Orchid
Biocomputer and Beckman Coulter to Collaborate Princeton, NJ, 3/22/99-Orchid
Biocomputer and Beckman Coulter entered a collaboration to develop a high-throughput technology for conducting massive single nucelotide polymorphism genotyping.
Affymetrix also entered an agreement with Research Genetics, by which Affymetrix will sell GeneChip arrays to Research Genetics, who will then offer screening and data analysis services based on the GeneChip platform...Boston Probes and Millipore entered a strategic alliance to jointly develop peptide nucleic acid probe-based tests for Millipore to distribute...Orchid
Biocomputer and Motorola entered a $15 million collaboration to enhance Orchid's microfluidic chips and further develop the technology.